



Oceanaa Biotek Industries Limited

Regd. Off.

15, Zackaria Colony, 4th Street, Choolaimedu,
Chennai - 600 094, India.

Corp. Off.

6,1st Floor, Wellington Estate,
53, Ethiraj Salai, Egmore, Chennai - 600 008. India.

T : + 91 44 3024 1900 F : + 91 44 3024 1990

E : obil@oceanaabiotek.com

CIN : L15549TN2005PLC057919

OBIL/BSE/133/2017-2018

11th August, 2017

To,
The Corporate Relations Department
The Bombay Stock Exchange Ltd,
P J Towers, 1st Floor,
Dalal Street,
Mumbai – 400 001

Dear Sir/Madam,

Ref: Scrip Code: **538019**

ISIN: INE732P01018

Sub: Submission of Standalone Unaudited Financial Results for the quarter ended 30th June, 2017.

This is to inform you that the meeting of the Board of Directors was held today, 11th August, 2017 inter alia, to consider and approve the Unaudited (limited reviewed) Financial Results for the quarter ended 30.06.2017.

In this regard, the following documents are enclosed herewith:

- Standalone Unaudited Financial Results for the quarter ended 30.06.2017 - Regulation 33 - Annexure I of SEBI (LODR) Regulations, 2015.
- Limited review report signed by the Statutory Auditor

The meeting commenced at 6:00 p.m. and concluded at 7:30 p.m.

Kindly update the above in your records.

Thanking You.

For **Oceanaa Biotek Industries Limited**

Vimalla Joseb
Managing Director

Encl: As above



Laboratory : Pudukkuppam Village,
Mandavai Post, Marakkanam,
Tindivanam Taluk, Villupuram District,
Tamil Nadu 604 303.

Tel : + 91 4147 302300

www.oceanaabiotek.com



Oceanaa Biotek Industries Limited

Regd. Off.

15, Zackaria Colony, 4th Street, Choolaimedu,
Chennai - 600 094, India.

Corp. Off.

6,1st Floor, Wellington Estate,
53, Ethiraj Salai, Egmore, Chennai - 600 008. India.
T : + 91 44 3024 1900 F : + 91 44 3024 1990
E : obil@oceanaabiotek.com
CIN : L15549TN2005PLC057919

To
The Board of Directors,
Oceanaa Biotek Industries Limited
No. 15, Zackaria Colony, 4th street,
Choolaimedu, Chennai – 600 094,
Tamil Nadu


Dear Sir/Madam,


We hereby confirm the following in respect of the unaudited financial statements for the quarter ended on 30th June, 2017 being presented before the Board at the meeting to be held on 11th August, 2017.

- (1) That to the best of our knowledge, the financial results do not contain any false or misleading statement of figures.
- (2) That to the best of our knowledge, the financial results do not omit any material fact which may make the statements or figures contained therein misleading.

Yours sincerely

Place: Chennai
Date: 11.08.2017




Vimala Joseb
Managing Director
DIN: 00849207

Laboratory : Pudukuppam Village,
Mandavai Post, Marakkanam,
Tindivanam Taluk, Villupuram District,
Tamil Nadu 604 303.
Tel : + 91 4147 302300
www.oceanaabiotek.com



Elangovan and Co.,
Chartered Accountants

No.15 (Old No.4), Dr. Ranga Road
Metro Homes, 3rd Floor
Mylapore, Chennai - 600 004
Ph: 044-24933267
Mobile: +91 9962078267
email: sathish@elangovanco.com
sathishssca@gmail.com

Annexure V
Limited Review Report


Review Report to
The Board of Directors
Oceanaa Biotek Industries Limited

We have reviewed the accompanying statement of unaudited financial results of **Oceanaa Biotek Industries Limited** for the period ended **30th June, 2017**. This statement is the responsibility of the Issuer's Management and has been approved by the Board of Directors/ committee of Board of Directors of the Issuer. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Issuer's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Elangovan & Co.
Chartered Accountants
Firm Regn. No. 006990S



S. Sathish Kumar
Partner
M.No: 226384



Place: Chennai
Date: 11/08/2017

M/S. OCEANAA BIOTEK INDUSTRIES LIMITED
CIN: L15549TN2005PLC057919
NO.15, ZACKARIA COLONY, 4TH STREET,
CHOOLAIMEDU, CHENNAI - 600094, TAMIL NADU

Statement of Standalone Audited Results for the quarter and period ended 30.06.2017

Part I ₹ in lakhs except earnings per share and share information/data

Quarter and Period ended 30/06/2017

S.No	Particulars	3 months ended	Preceeding months ended	Corresponding 3 months ended in the previous year	Previous Accounting Year ended
		30th June 2017 Unaudited	31st March 2017 Audited	30th June 2016 Unaudited	31st March 2017 Audited
Revenue from Operations					
I.	(a) Income from Operations	942.26	355.94	1,027.90	3,670.12
II.	(b) Other Income(net)	4.06	3.21	-	4.05
III.	Total Revenue	946.32	359.14	1,027.90	3,674.16
IV. Expenses					
	a. Cost of materials consumed	-	-	-	-
	b. Purchase of stock-in-trade	401.38	53.37	507.03	2,057.88
	c.Changes in inventory of finished goods,work-in-progress and stock-in-trade	215.59	-83.17	101.19	42.69
	d. Employee benefit expenses	33.45	47.00	60.65	205.20
	e. Finance costs	0.92	0.61	27.33	2.46
	f. Depreciation and amortisation expenses	80.36	27.75	0.61	110.25
	g. Other expenses	185.82	198.89	246.35	829.04
	Total Expenses	917.53	244.45	943.16	3,247.51
V.	Profit/(Loss) before exceptional and extraordinary items and tax (III-IV)	28.79	114.69	84.74	426.65
VI.	Exceptional Items	-	-	-	-
VII.	Profit / (Loss) before extraordinary items and tax (V-VI)	28.79	114.69	84.74	426.65
VIII.	Extraordinary Item	-	-	-	-
IX.	Profit before tax (VII-VIII)	28.79	114.69	84.74	426.65
X.	Tax expense				
	1 Current tax	38.50	39.69	25.92	164.17
	2 Deferred tax	16.57	8.01	-	-7.59
XI.	Profit / (Loss) for the period from continuing operations (VII-VIII)	-26.28	66.99	58.82	270.08
XII.	Profit / (Loss) from discontinuing operations	-	-	-	-
XIII.	Tax expenses of discontinuing operations	-	-	-	-
XIV.	Profit / (Loss) from discontinuing operations (after tax) (XII-XIII)	-	-	-	-
XV.	Profit (Loss) for the period (XI+XIV)	-26.28	66.99	58.82	270.08
XVI.	Earnings per equity Share				
	(1) Basic	-0.19	0.66	0.98	2.65
	(2) Diluted	-0.19	0.66	0.98	2.65
	See accompanying notes to the financial statements.				

Notes:

- The Audited Financial results were reviewed by the Audit Committee and taken on record by the Board of directors at their meeting held on 11th Aug, 2017
- Figures of the previous period/year are reclassified /regrouped or rearranged wherever necessary to make it comparable.
- There are no separate reportable segments for the half year and year ended 31st March, 2017 as per Accounting Standard 17 on segment reporting notified under the Companies (Accounting Standard) Rules 2014.
- There were no Investors' Complaints pending/received during the period.

For and on Behalf of Board of Directors

Vimalla Joseb
Managing Director
DIN:00849207



Place: Chennai
Date : 11/08/2017